Please use this identifier to cite or link to this item: https://doi.org/10.1136/jclinpath-2011-200082
DC FieldValue
dc.titleDual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours
dc.contributor.authorYan, B.
dc.contributor.authorChoo, S.N.
dc.contributor.authorMulyadi, P.
dc.contributor.authorSrivastava, S.
dc.contributor.authorOng, C.W.
dc.contributor.authorYong, K.J.
dc.contributor.authorPutti, T.
dc.contributor.authorSalto-Tellez, M.
dc.contributor.authorLim, G.S.D.
dc.date.accessioned2014-11-26T07:44:19Z
dc.date.available2014-11-26T07:44:19Z
dc.date.issued2011-12
dc.identifier.citationYan, B., Choo, S.N., Mulyadi, P., Srivastava, S., Ong, C.W., Yong, K.J., Putti, T., Salto-Tellez, M., Lim, G.S.D. (2011-12). Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. Journal of Clinical Pathology 64 (12) : 1097-1101. ScholarBank@NUS Repository. https://doi.org/10.1136/jclinpath-2011-200082
dc.identifier.issn00219746
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/109309
dc.description.abstractBackground: Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti- HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment. Aims/methods: The authors studied the prevalence of HER2 genomic amplification and overexpression in 85 ovarian tumours in the local patient cohort of this study, as well as the concordance rate between immunohistochemistry, fluorescent in situ hybridisation (FISH) and a dual-colour HER2/chromosome 17 centromere chromogenic in situ hybridisation (CISH) assay. Results: The authors identified HER2 genomic amplification and protein overexpression in 35.3% (6/17) and 29.4% (5/17), respectively, of primary ovarian mucinous carcinomas. No other cancer subtypes displayed HER2 amplification or protein overexpression. The authors also found a perfect concordance between FISH and dual-colour CISH analysis (κ coefficient 1.0, p
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1136/jclinpath-2011-200082
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentPATHOLOGY
dc.description.doi10.1136/jclinpath-2011-200082
dc.description.sourcetitleJournal of Clinical Pathology
dc.description.volume64
dc.description.issue12
dc.description.page1097-1101
dc.description.codenJCPAA
dc.identifier.isiut000297263100012
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

20
checked on Dec 8, 2019

WEB OF SCIENCETM
Citations

18
checked on Jul 8, 2019

Page view(s)

70
checked on Nov 29, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.